
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
In this video, Scarlett Gomez, MD, PhD, discusses the significance of the private public collaboration between the National Cancer Institute’s Surveillance Epidemiology, and End Results program and the Oncotype DX Genomic Prostate Score assay in investing patterns in prostate genomic testing.Gomez is a professor in the department of epidemiology and biostatistics at the University of California, San Francisco.